Sei Investments Co. Buys 394 Shares of STAAR Surgical (NASDAQ:STAA)

Sei Investments Co. boosted its stake in shares of STAAR Surgical (NASDAQ:STAA) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,087 shares of the medical instruments supplier’s stock after purchasing an additional 394 shares during the period. Sei Investments Co.’s holdings in STAAR Surgical were worth $718,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Texas Permanent School Fund Corp boosted its holdings in shares of STAAR Surgical by 1.0% in the 1st quarter. Texas Permanent School Fund Corp now owns 42,577 shares of the medical instruments supplier’s stock valued at $1,630,000 after buying an additional 407 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in STAAR Surgical by 3.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after acquiring an additional 418 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its stake in STAAR Surgical by 2.3% in the second quarter. Linden Thomas Advisory Services LLC now owns 20,721 shares of the medical instruments supplier’s stock valued at $987,000 after acquiring an additional 469 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of STAAR Surgical by 2.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock valued at $1,176,000 after acquiring an additional 500 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of STAAR Surgical by 1.5% during the 1st quarter. Russell Investments Group Ltd. now owns 36,931 shares of the medical instruments supplier’s stock worth $1,406,000 after purchasing an additional 555 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, September 19th. BTIG Research raised their price objective on STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Morgan Stanley lowered STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $50.00 to $37.00 in a report on Monday, July 15th. Canaccord Genuity Group cut their price target on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating for the company in a report on Thursday, August 8th. Finally, Stifel Nicolaus reduced their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, August 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $45.57.

STAAR Surgical Price Performance

STAA opened at $31.46 on Wednesday. The business has a fifty day simple moving average of $34.24 and a 200 day simple moving average of $40.14. STAAR Surgical has a 1 year low of $26.66 and a 1 year high of $52.68. The company has a market capitalization of $1.55 billion, a PE ratio of 101.48 and a beta of 0.59.

STAAR Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). STAAR Surgical had a net margin of 4.99% and a return on equity of 5.60%. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $95.22 million. During the same period in the previous year, the firm posted $0.23 EPS. The company’s revenue was up 7.3% compared to the same quarter last year. Equities analysts anticipate that STAAR Surgical will post 0.16 earnings per share for the current fiscal year.

Insider Transactions at STAAR Surgical

In related news, Director Arthur C. Butcher purchased 1,315 shares of STAAR Surgical stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $37.99 per share, with a total value of $49,956.85. Following the completion of the transaction, the director now directly owns 4,208 shares of the company’s stock, valued at $159,861.92. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.00% of the company’s stock.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.